cirrhosis of liver: A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
222 |
4. Check minimum number of eventsNone |
222 |
5. Include endpointsNone |
222 |
6. Filter based on genotype QC (FinnGen only) |
222 |
Control definitions (FinnGen only)
- Control exclude
- CIRRHOSIS_BROAD
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- K74
- Name in latin
- Fibrosis hepatis
Similar endpoints
↥List of similar endpoints to
Fibrosis of liver
based on the number of shared cases.
Similar with more cases:
- Fibrosis and cirrhosis of liver
- Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523
- Diseases of liver
- Gastrointestinal diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1501 | 735 | 747 |
| Only index persons | 1232 | 625 | 607 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 59.22 | 59.75 | 58.57 |
| Only index persons | 58.22 | 58.24 | 58.20 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 222 | 115 | 107 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.05 |
| Median age at first event (years) | 57.16 | 55.12 | 59.34 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 195
- Matched controls
- 1949
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K74.0
ICD-10 Finland
Hepatic fibrosis
+∞
282.3
195
*
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
+∞
57.1
52
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
56.9
43.9
51
12
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
13.2
37.5
71
81
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.8
33.6
118
358
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
+∞
27.8
26
*
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
23.7
26.0
37
19
A05AA02
ATC
ursodeoxycholic acid; oral
50.3
25.4
30
7
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
246.5
22.1
22
*
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
38.8
21.8
27
8
R74.0
ICD-10 Finland
Elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
29.5
21.1
28
11
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.5
18.7
81
264
C03DA01
ATC
spironolactone; oral
7.3
18.5
47
81
103
Kela drug reimbursment
Diabetes, insulin-treated
4.1
17.6
88
325
R18
ICD-10 Finland
Ascites
28.7
17.4
23
9
K74.3
ICD-10 Finland
Primary biliary cirrhosis
69.7
17.1
19
*
Z94.4
ICD-10 Finland
Liver transplant status
+∞
16.9
16
*
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
98.7
16.9
18
*
JCA22
NOMESCO Finland
Endoscopic ligature of oesophageal varices
+∞
15.8
15
*
JJC00
NOMESCO Finland
Allogenic transplantation of liver
+∞
15.8
15
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.0
15.7
56
146
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
27.6
15.0
20
8
A10BA02
ATC
metformin; oral
3.6
14.8
86
348
A10AE04
ATC
insulin glargine; parenteral
6.2
14.8
42
83
K76.9
ICD-10 Finland
Liver disease, unspecified
22.1
14.1
20
10
C03CA01
ATC
furosemide; systemic
3.5
13.3
76
298
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.4
12.7
76
306
T90
ICPC
Diabetes non-insulin dependent
3.5
12.3
71
276
K75.9
ICD-10 Finland
Inflammatory liver disease, unspecified
19.7
12.3
18
10
K73.2
ICD-10 Finland
Chronic active hepatitis, not elsewhere classified
49.9
12.0
14
*
K83.0
ICD-10 Finland
Cholangitis
32.3
11.8
15
5
L04AX01
ATC
azathioprine; systemic
7.7
11.6
27
40
JJ9AE
NOMESCO Finland
Ultrasound examination of liver transplant
+∞
11.6
11
*
127
Kela drug reimbursment
Transplant complication
16.8
11.0
17
11
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
5.1
10.8
35
80
C07AA05
ATC
propranolol; systemic
3.4
10.1
54
196
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
5.7
10.1
29
58
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
9.9
9.8
19
21
K73.80
ICD-10 Finland
Non-alcoholic fatty liver (NASH, Non Alcoholic Steatohepatitis)
104.9
9.5
10
*
K70.0
ICD-10 Finland
Alcoholic fatty liver
104.9
9.5
10
*
K72.9
ICD-10 Finland
Hepatic failure, unspecified
104.9
9.5
10
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
104.9
9.5
10
*
K70.4
ICD-10 Finland
Alcoholic hepatic failure
+∞
9.4
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
9.3
79
388
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
7.2
9.3
22
34
A41.9
ICD-10 Finland
Sepsis, unspecified
9.8
9.3
18
20
JN3AD
NOMESCO Finland
Abdominal CT examination
5.0
9.2
30
69
L04AD01
ATC
ciclosporin; systemic
16.6
9.2
14
9
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
16.6
9.2
14
9
B18.2
ICD-10 Finland
Chronic viral hepatitis C
38.6
9.1
11
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
5.2
9.1
28
61
SPAT1262
SPAT
Handing over of treatment supplies
3.1
8.9
55
217
A10BH01
ATC
sitagliptin; oral
4.1
8.5
34
96
K70.9
ICD-10 Finland
Alcoholic liver disease, unspecified
+∞
8.4
8
*
K74.2
ICD-10 Finland
Hepatic fibrosis with hepatic sclerosis
+∞
8.4
8
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
7.5
8.0
18
26
L04AA06
ATC
mycophenolic acid; systemic
11.5
7.9
14
13
D97
ICPC
Liver disease NOS
46.9
7.8
9
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.5
7.5
36
119
A10BB12
ATC
glimepiride; oral
5.1
7.5
23
50
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
3.5
7.4
35
115
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
4.7
7.3
24
56
JJ5AT
NOMESCO Finland
NA
+∞
7.3
7
*
K72.1
ICD-10 Finland
Chronic hepatic failure
+∞
7.3
7
*
R17
ICD-10 Finland
Hyperbilirubinaemia, with or without jaundice, not elsewhere classified
16.5
7.3
11
7
D64.9
ICD-10 Finland
Anaemia, unspecified
3.4
7.2
35
117
N17.9
ICD-10 Finland
Acute renal failure, unspecified
7.5
7.2
16
23
160
Kela drug reimbursment
exenatide
10.6
7.1
13
13
UJF30
NOMESCO Finland
Ileoscopy through colon
3.8
7.0
29
85
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
14.5
7.0
11
8
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.5
7.0
68
349
A07EA06
ATC
budesonide; oral, local oral
6.9
6.8
16
25
E11.6
ICD-10 Finland
Type 2 diabetes mellitus, with other specified complications
23.5
6.7
9
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.3
6.7
24
62
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
10.6
6.6
12
12
TPH07
NOMESCO Finland
Cathetrisation of artery
3.4
6.6
32
107
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.8
6.6
21
48
R50.9
ICD-10 Finland
Fever, unspecified
3.0
6.5
37
139
8170/3-C22.0
ICD-O-3
Hepatocellular carcinoma, NOS, of liver
72.1
6.5
7
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
6.5
97
606
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.1
6.4
36
133
TK800
NOMESCO Finland
Hemodialysis
9.7
6.4
12
13
A10AD05
ATC
insulin aspart; parenteral (insulins and analog. for injection, intermediate- or long-acting comb. with fast-acting)
11.6
6.4
11
10
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
7.5
6.3
14
20
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
18.8
6.3
9
5
A07AA11
ATC
rifaximin; oral
+∞
6.3
6
*
K74.5
ICD-10 Finland
Biliary cirrhosis, unspecified
+∞
6.3
6
*
I85.0
ICD-10 Finland
Oesophageal varices with bleeding
+∞
6.3
6
*
TJJ00
NOMESCO Finland
Percutaneous needle biopsy of liver
27.7
6.3
8
*
K29.6
ICD-10 Finland
Other gastritis
27.7
6.3
8
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
6.1
39
157
A10AE05
ATC
insulin detemir; parenteral
4.8
6.1
19
43
E66.00
ICD-10 Finland
Metabolic syndrome
4.1
6.0
22
58
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.3
6.0
29
97
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
16
30.27
58.16
1.6
1.3
—
—
—
0
0
95
251
5.87
36.37
3.2
2.3
25.3
22.5
%
0.74
80
211
87
214
6.04
36.02
2.3
1.7
1.6
1.5
%
0.58
71
185
97
269
5.63
34.96
3.4
2.3
2.4
2.3
g/l
0.86
88
246
18
10
19.50
22.33
7.0
2.1
84.3
100.2
%
—
18
10
18
10
19.50
22.33
2.8
1.4
0.8
1.1
g/l
—
18
10
57
144
4.98
21.91
18.5
6.7
10.0
9.5
mmol/l
0.22
57
139
126
594
3.59
19.73
4.8
2.3
56.1
56.6
u/l
0.05
121
543
69
219
4.12
19.59
13.1
5.6
1.1
1.0
mmol/l
0.40
69
203
101
425
3.53
18.73
3.7
2.0
3.6
3.0
mg/l
1.33
91
366
25
32
8.68
18.67
1.6
1.2
269.8
207.6
u/ml
0.47
13
19
32
57
6.39
17.84
7.3
2.2
1.6
1.4
mg/l
0.51
32
52
25
34
8.16
17.76
1.6
1.2
—
—
—
0
0
117
555
3.34
17.61
5.2
3.9
12.4
10.0
mg/mmol
0.15
77
338
17
15
12.19
16.40
1.3
1.3
56.1
49.6
u/l
—
12
10
21
26
8.82
16.03
1.8
1.3
—
—
—
0
0
139
762
3.20
15.82
5.1
2.6
150.3
126.4
ug/l
0.57
133
705
153
893
3.30
15.50
15.7
6.7
1.2
1.2
mmol/l
2.33
129
755
144
818
3.16
15.17
13.0
5.7
1.2
1.2
mmol/l
2.66
137
748
189
1280
4.21
14.56
12.5
3.0
166.8
46.8
u/l
6.79
184
1204
51
159
3.87
14.51
10.5
3.7
1.5
2.1
mmol/l
0.38
35
124
22
37
6.49
12.86
2.1
1.4
—
—
—
0
0
21
35
6.52
12.37
1.8
1.3
111.3
97.4
u/ml
—
6
11
163
1072
2.96
11.81
15.9
9.5
3.7
4.0
e9/l
1.85
150
941
24
49
5.37
11.50
1.6
1.2
—
—
—
0
0
165
1113
2.88
11.01
11.2
4.5
7.6
6.6
mmol/l
4.37
157
1043
76
369
2.61
9.78
1.8
1.7
456.9
475.3
pmol/l
0.20
65
310
21
44
5.17
9.75
2.4
1.7
—
—
—
0
0
38
126
3.43
9.68
2.1
1.6
—
—
—
0
0
14
8
18.55
9.53
1.0
1.1
—
—
—
0
0
62
279
2.70
9.23
2.5
1.8
—
—
—
0
0
53
223
2.81
8.96
13.3
20.9
1.4
1.4
inr
0.21
14
29
67
322
2.55
8.68
2.3
1.6
1324.4
1201.0
nmol/l
0.47
55
248
48
198
2.82
8.38
10.0
7.7
1.3
1.5
mmol/l
0.10
31
161
115
713
2.27
8.26
2.4
1.9
90.3
95.6
pmol/l
0.64
77
370
32
106
3.36
8.12
16.3
6.5
23.1
25.0
mmol/l
2.10
32
106
78
413
2.37
8.11
1.3
1.2
0.9
1.7
u/ml
0.88
24
115
16
31
5.48
8.06
4.2
2.4
2.8
5.4
e9/l
3.49
16
31
49
209
2.73
8.01
3.9
4.1
3.1
28.1
ug/l
0.65
42
171
16
32
5.31
7.79
4.3
3.0
53.1
60.7
%
1.24
16
32
84
484
2.18
6.96
5.3
2.7
372.8
6892.3
umol/l
2.22
73
409
32
117
3.03
6.89
7.1
3.0
1.0
1.6
mmol/l
0.19
22
89
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
49
4.15
6.87
3.8
2.0
0.3
0.4
u/ml
0.74
13
25
10
15
6.93
6.36
1.0
1.0
—
—
—
0
0
19
52
3.90
6.35
1.4
1.2
—
—
—
0
0
125
864
2.02
6.15
8.6
3.9
—
—
—
0
0
41
184
2.51
5.97
4.0
2.3
41.9
33.0
u/l
0.35
36
155
69
399
2.06
5.46
2.9
1.8
1.3
1.3
mg/l
0.09
57
317
19
58
3.49
5.44
2.4
1.4
—
—
—
0
0
101
669
1.94
5.42
5.3
3.0
—
—
—
0
0
73
434
2.02
5.34
4.6
2.2
—
—
—
0
0
34
149
2.51
5.19
9.1
7.1
1.6
1.2
mmol/l
1.36
34
143
42
203
2.32
5.18
2.5
1.8
—
—
—
0
0
71
422
2.00
5.18
1.9
1.5
20.7
20.7
nmol/l
0.00
64
359
17
50
3.60
5.14
2.7
2.5
168.7
115.6
ug/min
0.20
11
30
34
150
2.50
5.11
2.4
2.6
61.6
66.7
ml/min/173m2
0.25
17
67
16
47
3.59
4.84
2.0
1.6
—
—
—
0
0
16
48
3.51
4.70
2.0
1.6
—
—
—
0
0
12
29
4.32
4.69
2.3
1.3
—
—
—
0
0
84
548
1.86
4.55
3.8
2.9
1180.0
923.5
ng/l
0.41
67
464
13
35
3.88
4.43
2.1
1.5
—
—
—
0
0
7
6
11.99
4.30
6.7
1.5
21.1
32.0
umol/l
—
7
6
23
91
2.70
4.29
4.1
2.4
1.3
1.1
%
0.25
23
91
18
63
3.02
4.17
2.3
1.9
—
—
—
0
0
83
552
1.80
4.15
2.9
2.1
330.2
170.9
u/l
0.63
76
519
170
1397
1.93
4.14
7.3
4.0
20.2
11.2
mm/h
6.61
163
1277
39
202
2.13
4.05
2.4
1.7
—
—
—
0
0
37
190
2.14
3.92
5.2
3.6
—
—
—
0
0
11
31
3.68
3.53
1.6
1.5
—
—
—
0
0
119
908
1.67
3.47
5.6
3.5
0.0
0.0
estimate
0.00
29
177
76
516
1.72
3.43
5.5
2.9
0.7
0.4
e6/l
0.47
66
375
12
37
3.37
3.39
2.6
2.5
15.2
16.1
%
—
5
20
7
10
7.18
3.39
2.4
2.8
—
—
—
0
0
7
10
7.18
3.39
2.1
1.7
—
—
—
0
0
9
19
4.89
3.27
2.3
1.4
—
—
—
0
0
8
15
5.49
3.22
1.1
1.1
—
—
—
0
0
7
11
6.53
3.21
1.3
1.6
—
—
—
0
0
56
356
1.77
3.16
3.8
3.6
320.4
161.4
ng/l
0.36
38
272
17
69
2.59
3.04
1.8
1.8
—
—
—
0
0
12
40
3.11
3.02
1.7
1.6
—
—
—
0
0
9
23
4.03
2.80
1.2
1.6
—
—
—
0
0
9
23
4.03
2.80
2.4
1.4
—
—
—
0
0
13
48
2.81
2.77
1.2
1.5
274.2
235.6
miu/ml
—
5
21
93
696
1.58
2.75
5.1
3.7
25.2
31.1
ng/l
0.73
72
492
115
910
1.55
2.63
7.0
4.8
0.0
0.0
estimate
0.00
29
180
8
20
4.11
2.59
1.3
1.7
—
—
—
0
0
5
7
7.27
2.56
1.2
1.0
—
—
—
0
0
6
11
5.57
2.56
1.3
1.6
—
—
—
0
0
10
34
3.03
2.44
1.2
1.6
—
—
—
0
0
6
12
5.10
2.42
1.3
1.7
9.2
11.4
umol/l
—
6
12
14
59
2.47
2.34
4.2
2.8
—
—
—
0
0
13
53
2.54
2.32
1.3
2.0
34.9
38.1
g/l
1.03
13
46
6
13
4.71
2.28
4.0
2.8
—
—
—
0
0
14
60
2.42
2.27
2.4
1.7
—
—
—
0
0
93
720
1.50
2.26
5.8
3.6
—
—
—
0
0
9
29
3.19
2.25
1.9
1.3
—
—
—
0
0
13
55
2.45
2.16
1.9
2.3
0.6
1.0
g/l
0.18
13
50
9
31
2.98
2.09
1.1
1.6
—
—
—
0
0
6
15
4.08
2.05
1.2
1.2
—
—
—
0
0
113
923
1.46
2.04
5.8
3.5
0.0
0.0
estimate
0.00
24
171
7
21
3.41
1.98
2.4
1.5
—
—
—
0
0
5
11
4.62
1.95
1.0
1.2
14.3
8.6
ug/l
—
5
11
46
315
1.58
1.92
3.3
2.5
0.8
0.9
e6/l
0.11
31
176
19
100
1.98
1.92
1.8
1.6
—
—
—
0
0
43
291
1.59
1.89
3.5
2.7
4.0
1.8
e6/l
0.67
28
154
67
504
1.47
1.82
6.7
3.6
0.0
0.0
estimate
0.50
26
172
200
1857
1.78
1.80
34.7
13.6
18.2
22.9
mg/l
2.25
184
1463
5
13
3.91
1.72
1.8
2.9
—
—
—
0
0
8
167
0.46
1.54
1.8
1.8
—
—
—
0
0
7
28
2.55
1.46
1.3
1.6
—
—
—
0
0
7
28
2.55
1.46
1.1
1.6
—
—
—
0
0
5
16
3.17
1.44
1.0
1.1
—
—
—
0
0
6
22
2.77
1.44
1.3
2.2
548.7
562.8
e6/l
—
6
17
11
53
2.13
1.41
3.0
3.3
4.0
3.8
mmol/l
1.21
11
47
7
29
2.46
1.40
1.0
1.0
—
—
—
0
0
191
1781
1.52
1.35
5.6
4.0
1.5
1.3
mmol/l
3.18
176
1638
43
315
1.45
1.32
1.4
1.3
20.4
6.9
u/ml
0.47
18
119
9
43
2.14
1.32
2.3
1.4
—
—
—
0
0
197
1853
1.56
1.28
6.1
4.5
4.3
4.7
mmol/l
4.28
183
1727
18
108
1.73
1.26
2.7
2.8
4.0
4.5
pmol/l
1.81
13
98
6
25
2.44
1.25
2.0
4.3
—
—
—
0
0
10
49
2.09
1.24
1.5
1.4
—
—
—
0
0
187
1744
1.46
1.24
10.5
5.7
43.5
39.9
mmol/mol
3.01
179
1632
8
37
2.20
1.22
2.3
1.1
28.6
5.5
e6/l
—
8
28
8
37
2.20
1.22
2.4
1.3
1964.4
3261.9
e6/l
—
8
29
5
19
2.67
1.22
1.2
1.4
—
—
—
0
0
5
19
2.67
1.22
1.2
1.3
—
—
—
0
0
5
19
2.67
1.22
1.2
1.4
—
—
—
0
0
8
39
2.09
1.16
1.0
1.4
—
—
—
0
0
5
20
2.53
1.15
1.0
1.3
—
—
—
0
0
7
30
2.38
1.13
1.4
1.3
—
—
—
0
0
7
30
2.38
1.13
1.4
1.3
—
—
—
0
0
5
21
2.41
1.09
1.8
1.3
—
—
—
0
0
7
32
2.23
1.09
1.4
1.1
—
—
—
0
0
129
1155
1.28
1.01
2.6
2.9
—
—
—
0
0
194
1840
1.43
0.98
5.9
4.4
1.3
1.5
mmol/l
4.83
180
1706
152
1396
1.28
0.94
5.0
3.8
15.0
14.8
pmol/l
0.55
144
1264
6
28
2.17
0.92
1.3
1.6
—
—
—
0
0
6
28
2.17
0.92
1.3
1.6
—
—
—
0
0
6
29
2.10
0.90
1.5
1.9
—
—
—
0
0
6
29
2.10
0.90
1.3
1.6
—
—
—
0
0
6
29
2.10
0.90
1.3
1.6
—
—
—
0
0
8
42
1.94
0.89
1.3
1.3
—
—
—
0
0
8
43
1.89
0.88
2.0
1.3
—
—
—
0
0
180
1697
1.32
0.86
5.9
4.6
1.8
1.9
mu/l
0.53
173
1548
9
58
1.57
0.70
1.4
1.4
—
—
—
0
0
41
333
1.28
0.69
1.5
1.3
30.5
32.7
iu/ml
0.07
18
109
196
1886
1.34
0.66
6.7
5.0
2.5
2.8
mmol/l
4.82
184
1746
11
70
1.60
0.66
1.1
1.9
—
—
—
0
0
5
30
1.68
0.62
1.0
1.1
—
—
—
0
0
39
321
1.26
0.60
1.6
1.5
—
—
—
0
0
204
1984
1.35
0.54
39.2
15.9
82.4
77.4
umol/l
1.11
204
1984
76
683
1.17
0.49
4.3
4.7
2.1
2.0
ug/l
0.04
70
614
7
46
1.54
0.49
1.0
1.2
—
1.0
—
0
5
34
404
0.81
0.48
2.6
2.9
0.9
0.7
ug/l
0.42
24
263
7
48
1.47
0.47
1.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
598.9
—
0
9
0
17
0.00
0.41
0.0
1.1
—
44.8
—
0
8
60
539
1.16
0.39
1.7
1.7
1.6
1.4
mmol/l
0.57
50
453
6
44
1.37
0.34
1.2
1.3
—
—
—
0
0
14
112
1.27
0.29
2.4
1.4
—
—
—
0
0
5
38
1.32
0.23
1.6
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
6
48
1.26
0.20
1.2
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
14
157
0.88
0.11
2.0
2.4
14.8
13.6
nmol/l
0.20
14
147
13
146
0.88
0.10
1.7
2.0
—
—
—
0
0
6
55
1.09
0.09
1.3
1.1
—
—
—
0
0
6
55
1.09
0.09
1.3
1.1
—
—
—
0
0
6
58
1.04
0.08
2.5
1.7
—
—
—
0
0
184
1823
1.05
0.07
6.5
4.5
6.7
6.0
mmol/l
5.10
174
1685
9
101
0.89
0.06
1.3
1.3
—
—
—
0
0
169
1678
1.03
0.03
36.8
14.3
36.9
40.1
%
2.82
106
1223
24
249
0.96
0.03
1.3
1.4
—
—
—
0
0
24
233
1.03
0.01
17.7
7.0
—
—
—
0
0
177
1766
1.01
0.00
30.0
12.6
78.7
81.4
ml/min/173m2
0.71
156
1453
55
554
0.99
0.00
4.0
4.2
25.3
21.5
%
0.73
22
257
10
103
0.97
0.00
1.1
1.0
—
—
—
0
0
16
165
0.97
0.00
1.7
2.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
7
71
0.99
0.00
2.0
1.4
36.1
23.7
iu/l
—
7
61
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
7.8
—
0
5
6
65
0.92
0.00
1.5
2.0
—
—
—
0
0
8
80
1.00
0.00
2.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
99.3
—
0
6
5
56
0.89
0.00
1.2
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint FIBROLIV and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| FIBROLIV | 3.993 [3.15, 5.06] | < 0.001 |
| Birth year | 1.0 [0.99, 1.01] | 0.94 |
During the follow-up period (1.1.1998 — 31.12.2019), 199 out of 599 females with FIBROLIV died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| FIBROLIV | 5.7 [4.11, 7.91] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 263 out of 545 males with FIBROLIV died.
Mortality risk
Mortality risk for people of age
years, who have FIBROLIV.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.386% | 1.014% |
| 5 | 2.546% | 5.439% |
| 10 | 6.983% | 14.34% |
| 15 | 12.573% | 25.688% |
| 20 | 21.768% | 40.077% |
Relationships between endpoints
↥Index endpoint: FIBROLIV – Fibrosis of liver
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data